MedTrace Logo

Radiotherapy of Pelvic Lymph Nodes in High Risk Prostate Cancer - A Retrospective Analysis

NCT02998619 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2018-07-31

No results posted yet for this study

Summary

Men with high risk prostate cancer who underwent radiotherapy of the prostate/seminal vesicles or underwent postoperative radiotherapy including pelvic lymph nodes between 2010 and 2016 are analyzed retrospectively. The aims are to estimate progression-free survival as well as toxicity according to CTCAE v4.03.

Conditions

  • Prostatic Neoplasms Benign
  • Radiotherapy Side Effect
  • Lymph Node Disease

Interventions

RADIATION

Radiotherapy

Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes

Sponsors & Collaborators

  • Kantonsspital Graubuenden

    lead OTHER

Principal Investigators

  • Daniel R Zwahlen, MD, MBA · Kantonsspital Graubuenden

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-11-11
Completion
2018-06-19

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02998619 on ClinicalTrials.gov